SHORT REPORT

Environmental tobacco smoke and prevalent coronary heart disease among never smokers in the Scottish MONICA surveys

R Chen, R Tavendale, H Tunstall-Pedoe

A lthough many studies have shown that environmental tobacco smoke (ETS) or passive smoking increases the risk of coronary heart disease (CHD), there is still scepticism. This may be due to the small magnitude of the effect (about 25–35% increase), inadequate adjustment for confounding variables, and misclassification of passive smoking. To estimate exposure, the majority of previous studies used only self-report, without any biochemical markers, which could result in misclassification errors arising both from respondent and investigator biases. We analysed data from the Scottish MONICA surveys to see whether prevalent coronary heart disease is independently associated with passive smoking measured by self-report, serum cotinine, and their combination.

SUBJECTS AND METHODS

Risk factor surveys were conducted for the Scottish MONICA Project in North Glasgow in 1986, 1989, 1992, and 1995. Subjects were randomly recruited from general practitioner lists after stratification into 10 year age and sex groups. A total of 1262 aged 25–64 participated in the first, 1397 in the second, 1958 (including 442 aged 65–74) in the third, and 1836 in the fourth, with response rates of 63.5%, 59.0%, 65.5%, and 65.7% respectively. Participants completed a personal health record that incorporated questions on socio-demographic and health status including details of active and passive smoking, the Rose chest pain questionnaire, and a demographic and health status that incorporated questions on socio-

The four possible answers were: yes, a lot; yes, some; yes, a little; or no, none at all. We categorised them in reverse order as groups I, II, III, and IV. In surveys 3 and 4, the question was “Are you regularly exposed to tobacco smoke from other people?”; separate exposures at work, at home, and in other places were recorded, and a numerical score ranging from 1 to 4, corresponding to the groups above, was assigned for each defined location. To estimate total exposure, the three numerical scores were added together for subjects in full time employment; for the remaining subjects, the scores from at home and in other places were summed and then multiplied by a factor of 1.5 to make the total exposure (or score) equivalent to those in full time employment. This process gives a range of scores from 3 to 12. In order to combine the data from these surveys with those from the earlier ones, scores of 3–4 were defined as I, scores 5–6 as II, scores 7–8 as III, and scores 9–12 as IV. In surveys 3 and 4, an additional question was asked: “On average, for how many hours a day are you exposed to other people’s tobacco smoke?”.

Serum cotinine levels were categorised into four groups using cut points defined previously: no detectable cotinine, I; 0–1.05 ng/ml, II; 1.06–3.97 ng/ml, III; and 3.98–17.49 ng/ml, IV. Because self-report may involve misclassification, and serum cotinine level, an indicator of recent exposure over 1–2 preceding days, may be affected by time since the last passive smoking exposure (which raises the question of whether it is ideal to take cotinine concentration as a sole index of ETS exposure), we have recently suggested that a combination of self-report and serum cotinine would be a better measurement of ETS in adults. To generate the combined self-report and cotinine score, a numerical score ranging from 1 to 4 was assigned to each participant for each of the self report and cotinine groups into which they had been categorised, and the two scores were added together giving a possible range of 2–8, which were further categorised in ascending order as groups I–VII.

The SAS (Windows version 8.2; SAS Institute Inc., Cary, NC) statistical package was used to analyse the data. Similar to the previous analysis, coronary heart disease was categorised as questionnaire angina, undiagnosed CHD (included questionnaire angina), diagnosed CHD, and all CHD. Difference in prevalence of CHD between ETS groups were examined by the χ² test. The association of CHD to ETS was examined using a binary logistic regression model.

RESULTS

Table 1 shows the prevalence and odds ratios (OR) for CHD in relation to passive smoking. Questionnaire angina shows a

Main messages

- There was a weaker relation of CHD to serum cotinine than to self-reported ETS; but when cotinine was detected, a dose-response relation was observed.
- The combination of self-reported ETS and serum cotinine showed a clearer gradient of prevalent CHD with exposure.
- The association of CHD with ETS was independent of other cardiovascular confounders.
- The increased risk of CHD for those in full time employment seemed to be mainly from ETS exposure at work.

Policy implications

- The study further endorses current policies of strictly limiting smoke in public areas.
Table 1   Odds ratios for prevalent coronary heart disease across categories of passive smoking by self report, serum cotinine, and their combination

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Self reported exposure group</th>
<th>Serum cotinine group</th>
<th>Combination score derived from self report and cotinine groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All (n = 1854)</td>
<td>I (n = 314)</td>
<td>II (n = 776)</td>
</tr>
<tr>
<td>angina</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No positive</td>
<td>93</td>
<td>11</td>
<td>30</td>
</tr>
<tr>
<td>Prevalence (%)</td>
<td>5.0</td>
<td>3.5</td>
<td>5.3</td>
</tr>
<tr>
<td>Odds ratio</td>
<td>1.0</td>
<td>1.0</td>
<td>1.1</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.4–2.0</td>
<td>0.5–2.4</td>
<td>0.7–3.5</td>
</tr>
</tbody>
</table>

Undiagnosed CHD

| No positive | 300                         | 44                   | 115        | 71            | 70           | 254           | 63         | 52           | 105           | 34            | 8           | 45          | 55          | 48          | 43          | 35          | 20          |
| Prevalence (%)| 16.2                        | 14.0                 | 14.8      | 16.4          | 21.1          | 16.3          | 17.1       | 12.1         | 17.4          | 21.4          | 9.0          | 15.1         | 15.9        | 15.8        | 16.1        | 19.1        | 27.0        |
| Odds ratio   | 1.0                         | 1.2                  | 1.3       | 1.6*          | 1.1           | 1.0           | 0.6*       | 0.9          | 1.2           | 1.0           | 1.6         | 1.8         | 1.7         | 1.7         | 1.7         | 2.2         | 3.0*        |
| 95% CI       | 0.8–1.7                     | 0.8–1.9              | 1.0–2.5    |               |              | 0.4–0.9       | 0.6–1.3    | 0.7–1.9      | 0.7–3.5       | 0.8–3.9       | 0.7–3.5     | 0.7–3.6     | 0.9–4.7     | 1.2–7.3     |              |            |             |

Diagnosed CHD

| No positive | 85                          | 9                    | 30         | 24            | 22           | 75            | 14         | 19           | 35            | 7             | 3           | 8           | 15          | 19          | 8           | 5           |
| Prevalence (%)| 4.6                         | 2.9                  | 3.9        | 5.6           | 6.6          | 4.8           | 3.8        | 4.4          | 5.8           | 4.4           | 3.4         | 2.7         | 4.9         | 5.0         | 7.1         | 4.4         | 6.8         |
| Odds ratio   | 1.0                         | 1.0                  | 1.6       | 2.8*          | 2.8*         | 1.0           | 1.1        | 1.4          | 1.2           | 1.0           | 0.5         | 1.2         | 1.2         | 1.6         | 1.3         | 1.5         |             |
| 95% CI       | 0.6–3.4                     | 1.0–5.8              | 0.9–5.6    |               |              | 0.5–2.2       | 0.6–2.6    | 0.3–2.5      | 0.1–2.0       | 0.3–3.7       | 0.2–3.7     | 0.4–5.4     | 0.2–4.5     | 0.2–5.3     |              |            |             |

All CHD

| No positive | 385                         | 53                   | 145        | 95            | 92           | 329           | 77         | 71           | 140           | 41            | 11          | 53          | 72          | 63          | 62          | 43          | 25          |
| Prevalence (%)| 20.8                        | 16.9                 | 18.7      | 22.9          | 27.7          | 21.1          | 20.9       | 16.6         | 23.2          | 25.8          | 12.4        | 17.8        | 20.9        | 20.8        | 23.2        | 23.5        | 33.8        |
| Odds ratio   | 1.0                         | 1.0                  | 1.3       | 1.8*          | 2.0**         | 1.0           | 0.7        | 1.1          | 1.2           | 1.0           | 0.7         | 1.4         | 1.8         | 1.7         | 8.1         | 2.1         | 3.0**       |
| 95% CI       | 0.8–1.9                     | 1.0–2.3              | 1.2–2.9    |               |              | 0.5–1.0       | 0.7–1.4    | 0.7–1.8      | 0.6–2.6       | 0.8–3.3       | 0.7–3.0     | 0.8–3.6     | 0.9–3.9     | 1.1–6.0     |              |            |             |

1Odds adjusted for age, sex, educational level, employment status, BMI, systolic blood pressure; further adjusted for parents’ CHD history, alcohol drinking, dietary vitamin C and fibre, and serum total cholesterol.

Statistical significance: *p<0.05; **p<0.01; ***p<0.001; linear trend p: T1<0.05, T2<.01.
gradient of prevalence with increasing self reported exposure. The 300 cases of undiagnosed CHD further show a gradient of prevalence and a significant OR in the highest exposure group after adjustment for major coronary risk factors. With smaller numbers, diagnosed CHD shows raised ORs in the exposure groups. When all CHD categories are combined there is a regular, significant gradient. Results for serum cotinine do not corroborate self report completely. There was a higher prevalence of questionnaire angina, undiagnosed CHD, and all CHD in subjects with no detectable cotinine compared to those having cotinine levels >0–1.05 ng/ml, while the prevalence of diagnosed CHD was lowest in the group with no detectable cotinine. In the categories of questionnaire angina, undiagnosed CHD, and all CHD a significant, clear gradient of increased CHD risk with cotinine concentrations was found for those having detectable cotinine.

Using the combination score derived from self report and serum cotinine values, we observed a strong increase in CHD with increasing exposure for the questionnaire angina, undiagnosed CHD, and all CHD groups (table 1). This trend was not seen in the diagnosed CHD group, probably due to the smaller numbers of cases in each group (the increasing trend could be found if exposure groups I–II, III–IV, and V–VII were combined).

In surveys 3 and 4 (1114 subjects), we found a significant association of prevalent CHD with self reported ETS duration; compared to no exposure, the multiple adjusted OR for all CHD (253 cases) was 1.2 (0.8–1.9) for daily exposure of >0–2 hours, 1.6 (1.0–2.6) for 3–5 hours, and 1.7 (1.0–2.8) for over 6 hours (trend p = 0.138), while the combination with serum cotinine score further showed a similar gradient (data on request). Furthermore, the data of 502 subjects in full time employment indicated that the increased risk of all CHD (72 cases) seemed to be more closely related to ETS exposure at work (the multiple adjusted OR 1.7, 0.9–3.2 for those having any exposure compared to the no exposure group) than at home (1.2, 0.7–2.2) or in other places (1.0, 0.4–2.3).

DISCUSSION

The current study using the combined measure identified a consistent, dose-response relation between ETS and CHD. However, in separate analyses of ETS estimated by either self report or serum cotinine, there was a closer relation of CHD to self report, which was consistent with previous findings in the cross sectional data analysis for the Scottish Heart Health Study. An unexpected finding was the higher prevalence of CHD in the group with no detectable cotinine when compared to the group with the lowest level of detectable cotinine. A possible explanation is that the no detectable cotinine group contained a number of CHD patients who avoided ETS exposure. Other contributing factors could be: (1) the effect of delay in time between last ETS exposure and blood sampling; (2) cotinine data were missing for fewer (9% v 29%) of the MONICA 3&4 subjects than the surveys 1 and 2, where the finding was less apparent (see below); and (3) the capillary chromatographic method of cotinine analysis adopted for MONICA 3&4 was more sensitive (survey 1 used a packed column method but survey 2 used the same method as MONICA 3&4). It is arguable that the non-exposed group (that is, no detectable cotinine) should (or not) be included for the dose-response trend analysis, and that by excluding the never exposed groups, the linear trends of the dose-exposure relations would be more convincing if they showed a significant trend of higher risk with higher degrees of exposure. Restricting the data to subjects with detectable cotinine, we found a gradient of CHD with cotinine concentration in both MONICA surveys 3 and 4 (the multiple adjusted ORs for all CHD in cotinine groups II to IV were 0.9 (0.5–1.3), 1.4 (0.9–2.1), and 1.4 (0.7–2.6); trend p = 0.089) and MONICA surveys 1 and 2 (ORs were 0.4 (0.2–0.8), 0.5 (0.3–0.9), and 0.7 (0.3–1.6); trend p = 0.026). The magnitude of the gradient was similar to (or even greater than) that by self report in groups II to IV (see table 1).

In this study, the main limitations are its cross sectional design and a relatively small number of subjects to identify the small magnitude of the effects of ETS on CHD, which led to insufficient statistical power for some increased ORs and trends. A large cohort study using both self report, serum cotinine, and their combination is needed to further examine the effects. However, the standardised and extensive database from the MONICA surveys allowed analysis and control for many confounding demographic variables. Four ETS exposure degrees for both self report and serum cotinine and seven exposure groups for their combination gave us an opportunity of more accurately estimating the adverse association, and would be one of the reasons to explain that our data showed a greater effect of passive smoking than other studies which mainly used dichotomised ETS exposure estimation. The adverse association identified in self report, serum cotinine, and their combination was dose dependent, and not substantially changed by multiple adjustment for confounding variables. The findings have been further confirmed in a 14 year follow up of cardiovascular mortality in our Scottish Heart Health Study. For those in full time employment, the relation between ETS at work and CHD seemed to be greater compared to exposure at home and at other places. These findings, together with our previous investigations, strongly support current attempts to minimise passive exposure to tobacco smoke and limit smoking in public areas.

Authors’ affiliations

R Chen, R Tavendale, H Tunstall-Pedoe, Cardiovascular Epidemiology Unit, Institute of Cardiovascular Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

Funding: Chief Scientist Office, Scottish Executive Health Department and British Heart Foundation

Correspondence to: Dr R Chen, Department of Epidemiology and Public Health, UCL, 1–19 Torrington Place, London WC1E 6BT, UK; ruoling.chen@westminster-pct.nhs.uk

Accepted 24 March 2004

REFERENCES

Environmental tobacco smoke and prevalent coronary heart disease among never smokers in the Scottish MONICA surveys

R Chen, R Tavendale and H Tunstall-Pedoe

*Occup Environ Med* 2004 61: 790-792
doi: 10.1136/oem.2003.009167

Updated information and services can be found at:
http://oem.bmj.com/content/61/9/790

These include:

**References**
This article cites 8 articles, 4 of which you can access for free at:
http://oem.bmj.com/content/61/9/790#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/